Skip to main content

Home/ Cancer/ Group items tagged M

Rss Feed Group items tagged

Matti Narkia

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumul... - 0 views

  •  
    Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15. PMID: 19501932 CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.
Matti Narkia

Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2... - 0 views

  •  
    Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Blázquez C, Salazar M, Carracedo A, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M. Cancer Res. 2008 Mar 15;68(6):1945-52. PMID: 18339876 doi: 10.1158/0008-5472.CAN-07-5176
Matti Narkia

AICR: Policy Report: Policy and Action for Cancer Prevention - 0 views

  •  
    Policy Report\n\nLearn more about the new WCRF/AICR report, Policy and Action for Cancer Prevention, which was launched at an international press briefing in London at 10 a.m. GMT (5 a.m. US Eastern Time), and presented to US lawmakers at a Congressional Briefing at 10 a.m. US Eastern Time, on February 26th, 2009.
Matti Narkia

Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesi... - 0 views

  •  
    Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer, and S. D. Merajver Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis Canc
Matti Narkia

Pistachios may reduce lung cancer risk - 1 views

  •  
    "HOUSTON - A diet that incorporates a daily dose of pistachios may help reduce the risk of lung and other cancers, according to data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9. "It is known that vitamin E provides a degree of protection against certain forms of cancer. Higher intakes of gamma-tocopherol, which is a form of vitamin E, may reduce the risk of lung cancer," said Ladia M. Hernandez, M.S., R.D., L.D., senior research dietitian in the Department of Epidemiology at the University of Texas M. D. Anderson Cancer Center, and doctoral candidate at Texas Woman's University - Houston Center. "Pistachios are a good source of gamma-tocopherol. Eating them increases intake of gamma-tocopherol so pistachios may help to decrease lung cancer risk," she said. Pistachios are known to provide a heart-healthy benefit by producing a cholesterol-lowering effect and providing the antioxidants that are typically found in food products of plant origin. Hernandez and colleagues conducted a six-week, controlled clinical trial to evaluate if the consumption of pistachios would increase dietary intake and serum levels of gamma-tocopherol. A pistachio-rich diet could potentially help reduce the risk of other cancers from developing as well, according to Hernandez. "Because epidemiologic studies suggest gamma-tocopherol is protective against prostate cancer, pistachio intake may help," she said. "Other food sources that are a rich source of gamma-tocopherol include nuts such as peanuts, pecans, walnuts, soybean and corn oils.""
Matti Narkia

Optimal Vitamin D Status for Colorectal Cancer Prevention: A Quantitative Meta Analysis... - 0 views

  •  
    Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007 Mar;32(3):210-6. PMID: 17296473 [
Matti Narkia

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliver... - 0 views

  •  
    Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.
Matti Narkia

Selenium and immunocompetence in patients with head and neck cancer. - Biol Trace Elem ... - 0 views

  •  
    Selenium and immunocompetence in patients with head and neck cancer. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R. Biol Trace Elem Res. 2000 Feb;73(2):97-111. PMID: 11049203 DOI: 10.1385/BTER:73:2:97
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

  •  
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21. PMID: 18645193 DOI: 10.1200/JCO.2007.15.9749
Matti Narkia

Arginine deprivation as a targeted therapy for cancer. - Curr Pharm Des. 2008 - Bentham... - 0 views

  •  
    Arginine deprivation as a targeted therapy for cancer. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Curr Pharm Des. 2008;14(11):1049-57. Review. PMID: 18473854
Matti Narkia

Prospective study of predictors of vitamin D status and survival in patients with color... - 0 views

  •  
    Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer K Ng, B M Wolpin, J A Meyerhardt, K Wu, A T Chan, B W Hollis, E L Giovannucci, M J Stampfer, W C Willett and C S Fuchs Br J Cancer 101: 916-923; advance online publication, August 18, 2009; doi:10.1038/sj.bjc.6605262
Tom Scott

The Politics of Lung Cancer - 0 views

  •  
    A great Huffington Post op-ed from cancer prevention expert Samuel S. Epstein, M.D.
Matti Narkia

Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. - Cance... - 0 views

  •  
    Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M. Cancer Res. 2004 Aug 15;64(16):5617-23. PMID: 15313899
Matti Narkia

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC)... - 0 views

  •  
    Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Eur Urol. 2005 Apr;47(4):449-54; discussion 454-5. Epub 2005 Jan 19. PMID: 15774240 doi:10.1016/j.eururo.2004.12.001
Matti Narkia

Cannabinoids and cancer: causation, remediation, and palliation : The Lancet Oncology - 0 views

  •  
    Cannabinoids and cancer: causation, remediation, and palliation. Hall W, Christie M, Currow D. Lancet Oncol. 2005 Jan;6(1):35-42. Review. PMID: 15629274 doi:10.1016/S1470-2045(04)01711-5
Matti Narkia

Cannabinoids: potential anticancer agents : Abstract : Nature Reviews Cancer - 0 views

  •  
    Cannabinoids: potential anticancer agents. Guzmán M. Nat Rev Cancer. 2003 Oct;3(10):745-55. Review. PMID: 14570037 doi:10.1038/nrc1188
Matti Narkia

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agent... - 0 views

  •  
    Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. PMID: 19285265 doi:10.1016/j.beem.2009.02.001    
Matti Narkia

Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer : The Lance... - 0 views

  •  
    Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Druesne-Pecollo N, Tehard B, Mallet Y, Gerber M, Norat T, Hercberg S, Latino-Martel P. Lancet Oncol. 2009 Feb;10(2):173-80. Review. PMID: 19185835 doi:10.1016/S1470-2045(09)70019-
Matti Narkia

Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mende... - 0 views

  •  
    Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mendelian randomization approach. Boccia S, Hashibe M, Gallì P, De Feo E, Asakage T, Hashimoto T, Hiraki A, Katoh T, Nomura T, Yokoyama A, van Duijn CM, Ricciardi G, Boffetta P. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):248-54. PMID: 19124505 doi: 10.1158/1055-9965.EPI-08-0462
Matti Narkia

Access : Tumours with PI3K activation are resistant to dietary restriction : Nature - 0 views

  •  
    Tumours with PI3K activation are resistant to dietary restriction. Nada Y. Kalaany & David M. Sabatini Nature. Published online 11 March 2009 doi:10.1038/nature07782
1 - 20 of 81 Next › Last »
Showing 20 items per page